- Home
- ROMA vs IKT Comparison
ROMA vs IKT Comparison
Compare ROMA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- IKT
- Stock Information
- Founded
- ROMA 2018
- IKT 2008
- Country
- ROMA Hong Kong
- IKT United States
- Employees
- ROMA N/A
- IKT N/A
- Industry
- ROMA Savings Institutions
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ROMA Finance
- IKT Health Care
- Exchange
- ROMA Nasdaq
- IKT Nasdaq
- Market Cap
- ROMA 160.8M
- IKT 140.5M
- IPO Year
- ROMA 2024
- IKT 2020
- Fundamental
- Price
- ROMA $2.65
- IKT $1.89
- Analyst Decision
- ROMA
- IKT Buy
- Analyst Count
- ROMA 0
- IKT 2
- Target Price
- ROMA N/A
- IKT $8.00
- AVG Volume (30 Days)
- ROMA 53.1K
- IKT 100.4K
- Earning Date
- ROMA 09-02-2025
- IKT 08-14-2025
- Dividend Yield
- ROMA N/A
- IKT N/A
- EPS Growth
- ROMA N/A
- IKT N/A
- EPS
- ROMA N/A
- IKT N/A
- Revenue
- ROMA $1,568,345.00
- IKT N/A
- Revenue This Year
- ROMA N/A
- IKT N/A
- Revenue Next Year
- ROMA N/A
- IKT N/A
- P/E Ratio
- ROMA N/A
- IKT N/A
- Revenue Growth
- ROMA 23.21
- IKT N/A
- 52 Week Low
- ROMA $0.50
- IKT $1.12
- 52 Week High
- ROMA $4.66
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ROMA 42.54
- IKT 58.05
- Support Level
- ROMA $2.56
- IKT $1.56
- Resistance Level
- ROMA $2.81
- IKT $1.86
- Average True Range (ATR)
- ROMA 0.27
- IKT 0.17
- MACD
- ROMA -0.03
- IKT 0.03
- Stochastic Oscillator
- ROMA 25.25
- IKT 97.94
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.